EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Treatment of recurrent aphthous stomatitis with oral roflumilast, a multicenter observational study

Rodrigo Peñuelas Leal iD, Leticia Bagan iD, Andrés Grau Echevarría iD, Jose Amancio Peñuelas Ruiz, Violeta Zaragoza Ninet, Jose Luis Sánchez Carazo, Gemma Pérez Pastor, Carolina Labrandero Hoyos iD, Malena Finello iD, Sandra Martínez Fernández iD, Daniel Blaya Imbernon iD, Ángel González García iD und 3 weitere

International Journal of Dermatology · 2024-12 · 63 (12)

DOI: 10.1111/ijd.17478 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Dermatology, online erschienen am 20.09.2024. Verfasst von Rodrigo Peñuelas Leal und 14 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, Consorci Hospital General Universitari de Valencia, Valencia, Spain. Hauptthemen laut MEDLINE: Aminopyridines, Benzamides, Cyclopropanes, Stomatitis, Aphthous. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Severe recurrent aphthous stomatitis (RAS) represents a therapeutic challenge because of its impact on the patient's quality of life. Additionally, no approved systemic therapies are available. Roflumilast, a phosphodiesterase‐4 inhibitor, has shown promise in other inflammatory dermatological conditions. This study aimed to assess the characteristics, effectiveness, and safety of roflumilast in treating RAS in routine clinical practice.

Methods

This is a single cohort ambispective observational study conducted in five Spanish centers. Twenty‐two patients with RAS treated with roflumilast participated. Data collection included demographic, clinical, and outcome variables. Statistical analysis compared the outcomes of 12 weeks of roflumilast treatment with a similar prior period without treatment.

Results

During treatment with roflumilast, a significant reduction in flare‐ups (88%) and oral ulcers (94%) was observed compared to the untreated period. A reduction in pain (66%) and ulcer duration (63%) was observed. Adverse effects (AEs) occurred in 13 patients, predominantly headache and gastrointestinal disturbances. Most of these were self‐limiting or manageable with dose adjustment. Treatment was withdrawn in three cases, mainly because of AEs.

Conclusions

This study suggests that roflumilast may effectively treat RAS by reducing the number of flare‐ups and ulcers, their duration, and the symptomatology produced by the ulcers. In addition, roflumilast has a good safety profile, is well tolerated at low doses, and does not require close monitoring. These characteristics and its favorable economic profile make roflumilast a promising therapeutic option in this pathology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminopyridinesBenzamidesCyclopropanesStomatitis, AphthousPhosphodiesterase 4 InhibitorsHumansMaleFemaleAdultMiddle AgedAdministration, OralYoung AdultTreatment OutcomeSymptom Flare UpRecurrenceHeadacheOral Ulcer

Stichwörter der Autor:innen

inflammatory diseasesoral diseasesoral mucosaoral ulcerphosphodiesterase 4recurrent aphthous stomatitisroflumilast

Substanzen

RoflumilastAminopyridinesBenzamidesCyclopropanesPhosphodiesterase 4 Inhibitors

Autor:innen und Institutionen

  • Dermatology Department, Consorci Hospital General Universitari de Valencia, Valencia, Spain.
  • Oral Medicine Department, University of Valencia, Valencia, Spain.
  • Gandia Public Health Centre, Gandía, Spain.
  • Dermatology Department, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain.
  • Pharmacology Department, University of Valencia, Valencia, Spain.
  • Department of Oral and Maxillofacial Surgery, Consorci Hospital General Universitari de Valencia, Valencia, Spain.

ORCID-Profile: Rodrigo Peñuelas Leal, Leticia Bagan, Andrés Grau Echevarría, Carolina Labrandero Hoyos, Malena Finello, Sandra Martínez Fernández, Daniel Blaya Imbernon, Ángel González García, Jose Bagan

Zitieren

APA

Peñuelas Leal, R., Bagan, L., Grau Echevarría, A., Peñuelas Ruiz, J. A., Zaragoza Ninet, V., Sánchez Carazo, J. L., Pérez Pastor, G., Labrandero Hoyos, C., Finello, M., Martínez Fernández, S., Blaya Imbernon, D., González García, Á., Pérez Zafrilla, E., Martí Cabrera, M., & Bagan, J. (2024). Treatment of recurrent aphthous stomatitis with oral roflumilast, a multicenter observational study. International Journal of Dermatology, 63(12). https://doi.org/10.1111/ijd.17478

Vancouver

Peñuelas Leal R, Bagan L, Grau Echevarría A, Peñuelas Ruiz JA, Zaragoza Ninet V, Sánchez Carazo JL, et al. Treatment of recurrent aphthous stomatitis with oral roflumilast, a multicenter observational study. International Journal of Dermatology. 2024;63(12). doi:10.1111/ijd.17478

BibTeX
@article{PeuelasLeal2024,
  author = {Peñuelas Leal, Rodrigo and Bagan, Leticia and Grau Echevarría, Andrés and Peñuelas Ruiz, Jose Amancio and Zaragoza Ninet, Violeta and Sánchez Carazo, Jose Luis and Pérez Pastor, Gemma and Labrandero Hoyos, Carolina and Finello, Malena and Martínez Fernández, Sandra and Blaya Imbernon, Daniel and González García, Ángel and Pérez Zafrilla, Elena and Martí Cabrera, Miguel and Bagan, Jose},
  title = {Treatment of recurrent aphthous stomatitis with oral roflumilast, a multicenter observational study},
  journal = {International Journal of Dermatology},
  year = {2024},
  volume = {63},
  number = {12},
  doi = {10.1111/ijd.17478}
}
Kostenlos starten →